| 26.19 1.29 (5.18%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 33.02 | 1-year : | 35.88 |
| Resists | First : | 28.27 | Second : | 30.71 |
| Pivot price | 26.26  |
|||
| Supports | First : | 24.3 | Second : | 20.22 |
| MAs | MA(5) : | 25.85 |
MA(20) : | 26.77 |
| MA(100) : | 18.17 |
MA(250) : | 16.23 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 29.5 |
D(3) : | 28.3 |
| RSI | RSI(14): 52.8 |
|||
| 52-week | High : | 42.26 | Low : | 6.42 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RAPP ] has closed above bottom band by 48.1%. Bollinger Bands are 35.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 26.22 - 26.32 | 26.32 - 26.41 |
| Low: | 24.57 - 24.69 | 24.69 - 24.8 |
| Close: | 25.97 - 26.18 | 26.18 - 26.36 |
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
Wed, 10 Sep 2025
Rapport Therapeutics Prices $250 Million Common Stock Offering - MarketScreener
Wed, 10 Sep 2025
Rapport Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock - Quiver Quantitative
Tue, 09 Sep 2025
Rapport Therapeutics prices $250 million public offering at $26 per share - Investing.com
Tue, 09 Sep 2025
$250 Million Stock Offering: Neurological Drug Developer Rapport Therapeutics Raises Growth Capital - Stock Titan
Mon, 08 Sep 2025
Rapport Therapeutics launches $250 million public stock offering - Investing.com
Mon, 08 Sep 2025
Why Did Rapport Therapeutics, Inc Shares Skyrocket in Premarket? - Tokenist
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 46 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 4.9 (%) |
| Held by Institutions | 89.6 (%) |
| Shares Short | 3,030 (K) |
| Shares Short P.Month | 3,150 (K) |
| EPS | 1.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.2 % |
| Return on Equity (ttm) | -29.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -76 (M) |
| Levered Free Cash Flow | -51 (M) |
| PE Ratio | 21.82 |
| PEG Ratio | 0 |
| Price to Book value | 3.62 |
| Price to Sales | 0 |
| Price to Cash Flow | -15.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|